Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.
Dulaglutide is indicated as an add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||04/03/2015|
|Rapid review completed||29/04/2015|
|Rapid Review outcome||Full pharmacoeconomic assessment not recommended|